Roche Holding AG (XSWX:RO) NonCurrent Deferred Revenue: CHF116 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:RO Roche Holding AG XSWX:RO
79 GF Score
Price CHF337.40
GF Value CHF268.90
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG NonCurrent Deferred Revenue?

Roche Holding AG XSWX:RO +0.24% 79 NonCurrent Deferred Revenue is CHF116 Mil as of Dec. 2025. GuruFocus rates XSWX:RO with a GF Score™ of 79/100 and a GF Value™ of CHF268.90 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Roche Holding AG's non-current deferred revenue for the quarter that ended in Dec. 2025 was CHF116 Mil.

Roche Holding AG NonCurrent Deferred Revenue Related Terms

Roche Holding AG NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG NonCurrent Deferred Revenue Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 246.00 254.00 227.00 160.00 116.00

Roche Holding AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.00 0.00 160.00 0.00 116.00
XSWX:RO
79GF Score
Roche Holding AG XSWX:RO
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of CHF116 Mil mean?
Roche Holding AG (XSWX:RO) has a NonCurrent Deferred Revenue of CHF116 Mil as of Dec. 2025. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Roche Holding AG and its competitors.
Is Roche Holding AG's NonCurrent Deferred Revenue too high?
Roche Holding AG's current NonCurrent Deferred Revenue is CHF116 Mil. Overall, Roche Holding AG has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roche Holding AG's NonCurrent Deferred Revenue compare to LLY and JNJ?
Roche Holding AG's NonCurrent Deferred Revenue of CHF116 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Drug Manufacturers company?
A good NonCurrent Deferred Revenue depends on the Drug Manufacturers industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Roche Holding AG and its competitors. Roche Holding AG's current NonCurrent Deferred Revenue is CHF116 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roche Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Roche Holding AG (XSWX:RO) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF268.90, compared to a current price of CHF337.40 — trading 25.5% above its estimated fair value. The current NonCurrent Deferred Revenue is CHF116 Mil. Roche Holding AG's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Roche Holding AG (XSWX:RO), the current NonCurrent Deferred Revenue is CHF116 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roche Holding AG (XSWX:RO) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of CHF337.40 is trading 25.5% above its estimated GF Value™ of CHF268.90. GuruFocus considers Roche Holding AG to be Modestly Overvalued.

Key valuation signals for XSWX:RO:

  • NonCurrent Deferred Revenue: CHF116 Mil
  • GF Value™: CHF268.90 vs. price of CHF337.40 (25.5% above fair value)
  • GF Score™: 79/100 with 7 warning signs

No single metric tells the full story. See the XSWX:RO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
79GF Score

Get the complete analysis for XSWX:RO

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF337.40
Price
CHF268.90
GF Value